The developer of the coronavirus vaccine RBT raised 155 million rubles for the development of new vaccines. The funds were received during a private placement on the investment platform of the Skolkovo Resident Rounds, 860 people became shareholders of RBT.
Biotech startup RBT (Development of Biotechnologies) raised 155 million rubles for the development of new vaccines. This was reported to RB.RU in the Skolkovo press service, of which RBT is a resident.
Funds were received from angel investors during a private placement on the Rounds investment platform. Approved placement with oversubscription at top edge. The number of applications from potential investors exceeded 251 million rubles, Skolkovo said.
“With the opportunity to receive a profit from the Skolkovo Fund, a repayment of up to 50% of the amount of investments, 59 people have invested in RBT in the amount of 110 million rubles,” the fund noted.
RBT is a member of the Human Stem Cell Institute group. He is the developer of one of the vaccines against the coronavirus, Betuvax-Kov-2, and influenza, TetraFluBet.
The Rounds investment platform allows you to trade shares of private and non-public companies in Russia in an online format by creating a JSC. The investor has an opportunity to acquire a stake in a promising company at the stages of preSeed, Seed, Series A, B, C, preIPO. The money received from the sale of shares, the company can immediately use to finance its development.
In May 2023, Rounds raised 18 million rubles by selling 5% of its shares to current shareholder Vladimir Kozlov.
Author:
Kirill Bilyk
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
